AUSTRALIAN pharmaceutical manufacturer Phebra has welcomed the findings of a new study demonstrating the sustained benefits of giving neonatal caffeine to pre-term babies suffering breathing difficulties.
The Royal Women's Hospital in Melbourne led the research, following the development of 142 premature babies up to the age of 11, showing the rate of breathing difficulties was approximately halved for the neonates who had been given caffeine once per day.
Phebra was not involved in the study, but has developed the TGA-approved Cafnea range of products for the short-term treatment of apnoea of prematurity in infants of gestational age 28 to 33 weeks.
Phebra ceo Mal Eutick said it was the first time research had clearly demonstrated the long-lasting effectiveness of treating premature babies with caffeine.
The above article was sent to subscribers in Pharmacy Daily's issue from 21 Jul 17
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 21 Jul 17